Training Course

ADME, PK/TK, and Drug Metabolism in Drug Discovery and Development

January 23rd and 24th 2007
Sheraton Brussels Hotel and Towers
Brussel, Belgium

Who Should Attend

This course is specifically designed for personnel in the pharmaceutical and biotechnology industries and contract research organizations (CROs) who need to understand the requirements for ADME (absorption, distribution, metabolism, elimination), pharmacokinetics (PK) and toxicokinetics (TK), and drug metabolism (DM) experiments during the drug discovery and development processes.

Participants should have some knowledge of these processes and desire to learn more about how ADME, PK/TK, and DM studies are designed, conducted, and interpreted in order the characterize the fate of a drug candidate. Nonclinical and clinical scientists, managers, and project team leaders at pharmaceutical companies and related industries will gain a detailed understanding of the types of ADME, PK/TK, and DM research studies conducted to support submissions to regulatory authorities.

Learning Objectives

Upon completing this course, participants will have knowledge of the research studies conducted to characterize the fate of a drug candidate, either a small organic molecule (NCE) or macromolecule, after administration to animal models and humans. Participants will learn about and understand the requirements for ADME, PK/TK, and DM studies conducted to select the optimal drug discovery lead (developability assessment), to support first-in-human clinical trials, and to compare and extrapolate metabolism profiles from animal models to humans.

Course Description

The content of this course will assist pharmaceutical, biotechnology, and CRO researchers and managers in understanding the requirements for a well-designed and successful ADME, PK/TK, and DM program that is conducted within a drug development logic plan and in compliance ICH guidelines. The various types of ADME, PK/TK, and DM studies, which include in vitro metabolism and delivery, animal and human pharmacokinetics, protein binding, mass balance, tissue distribution, metabolite isolation and identification, and toxicokinetic support, will be discussed. Study designs and potential results, with possible interpretations, from each of the study types will be presented. The generation study reports and summaries, both of which are to be included in submissions to regulatory authorities, for completed research experiments will be delineated.
Course Instructor

The course will be taught by Dr. Duane Lakings. Dr. Lakings has over 25 years of experience in drug discovery and developability assessment, preclinical and non-clinical development, and clinical development and has designed and conducted animal and human research studies on both small organic molecules and macromolecules. His primary areas of expertise include pharmacokinetics and toxicokinetics, drug metabolism and ADME, drug delivery, and bioanalytical chemistry and he has excellent knowledge of the pharmacology, toxicology, and clinical requirements for successful drug development.

During his career, he has been involved in characterizing drug candidates for a number of therapeutic diseases and disorders, including CNS, cardiovascular, metabolic diseases, oncology, infectious diseases (bacterial and viral), and dermatology. He has used his knowledge to assist clients with defining drug development logic plans, selecting and managing CROs, and preparing study reports for completed nonclinical and clinical research studies.

Dr. Lakings has authored over 40 publications, 10 commissioned reports, 5 book chapters, and over 200 company-specific technical reports. He has made numerous scientific presentations at various society meetings and as an invited speaker at pharmaceutical and biotechnology companies. His expertise in the pharmacology and toxicology aspects of drug development and his experience in the research studies needed for the characterization of drug candidates and in scientific document preparation have led to many successful submissions to regulatory authorities.

Dr. Lakings is a member of many professional societies and associations, including the American Association for the Advancement of Science, American Association of Pharmaceutical Scientists, American Chemical Society, International Society for the Study of Xenobiotics, American Medical Writers Association, the Society of Sigma Xi, and Alpha Chi Sigma.

COURSE AGENDA

DAY ONE

Session 1: Introduction and Overview (8:30 – 10:00 AM)
- Purpose and Goals
- Drug Discovery and Development Logic Plan
- Types of Drug Metabolism and ADME Studies
- GLP Regulations Overview

Session 2: Developability Assessment Experiments (10:30 AM to noon)
- In Vitro Delivery and Example Profiles
- Preliminary Protein Binding
- In Vitro Metabolism
- Bioanalytical Chemistry Method Definition
- Preliminary Pharmacokinetics and Example Profiles
- Bioavailability and Example Profiles
Session 3: Preclinical Drug Development Experiments – Part 1 (1:00 to 2:30 PM)
- Bioanalytical Chemistry Method Validation
- Pharmacokinetic Assessments in Toxicology and Pharmacology Animal Species
- Absolute Bioavailability and Dose Proportionality Examples

Session 4: Preclinical Drug Development Experiments – Part 2 (3:00 to 4:30 PM)
- Toxicokinetics
- Multiple Dose Evaluation Examples
- Gender Effect Examples
- Drug Candidate Radioisotopic Labeling
- Choice of Label and Labeling Site
- Radiochemical and Metabolic Stability Evaluations
- Mass Balance in Toxicology Species
- Metabolic Profiling Assay
- Study Design and Sampling Recommendations
- Extent of Metabolism
- Route(s) and Rate(s) of Elimination
- Definitive Protein Binding in Various Species

DAY TWO

Session 5: Clinical Drug Development Experiments (8:30 to 10:00 AM)
- Types of Human ADME and Drug Metabolism Experiments
- Human Pharmacokinetic Evaluation Examples
- Drug-drug and Drug-Food Interactions
- Stereochemistry Issues
- Bioavailability and Bioequivalence Evaluations
- Renal and Hepatic Impairment Studies
- Age Effects

Session 6: Nonclinical Drug Development Experiments (10:30 AM to noon)
- Toxicokinetic Support
- Feto-placenta Transfer and Lacteal Secretion Toxicokinetic Studies
- Tissue Distribution (Single– and Repeat–Dose) and Whole Body Audioradiography
- Studies Design and Sampling Requirements
- Metabolite Isolation and Identification
- Development and Validation of Bioanalytical Method(s) for Metabolites
- Pharmacokinetic Evaluation of Metabolites
- Definition of Metabolism Pathway
- Induction and Inhibition of Drug Metabolizing Enzymes
- Animal Bridging Studies

Session 7: Clinical Drug Metabolism and ADME (1:00 to 2:30 PM)
- Study Protocols
- Technical/Study Reports
- Test Assay Methods
- Standard Operating Procedures
- Summaries for Submission to Regulatory Authorities

Session 8: Documentation (3:00 to 4:30 PM)
- Summary and Conclusions
- Workshop to Design and Discuss ADME and Drug Metabolism Studies Needed to Support the Discovery and Development of Various Drug Candidate Types – The Logical Approach to Discovery Lead Selection

For more information contact:

Cristina Lungu
Event Coordinator

Tel + 40 31 104 2183
Fax + 40 21 223 6500
cristinah@mondialresearchgroup.com

www.mondialresearchgroup.com
Please complete this form and fax it to:

Fax Number: 0040 21 223 6500
or email: catalina@mondialresearchgroup.com

| Company: |  |
| Address: |  |
| City: |  |
| Phone: | Fax: |
| E-mail: |  |

| Name: | Position: | E-mail: |
| Name: | Position: | E-mail: |
| Name: | Position: | E-mail: |

Authorisation

Signature: __________ Date:________

Mondial Research Group Ltd Fees

- **Course Fee**: £1695
- **Discount 2 or more people**: £1440
- **Discount Academia/Government**: £935

Fees are inclusive of programme materials, refreshments, and lunch.

**Payment Method**

- [ ] COMPANY CHEQUE
- [ ] BANK TRANSFER

**CONFIRMATION DETAILS**: Upon receipt of your registration an invoice will be issued. Once we have received payment, a letter outlining the course details will be sent. If you have not received this two weeks prior to the event, please contact the Conference Coordinator at info@mondialresearchgroup.com

**Payment is required within 5 working days of invoice**

**Venue will be confirmed one month prior to event**

**Terms & Conditions:**

1. Fees are inclusive of programme materials and refreshments.
2. Payment Terms: Following completion and return of the registration form, full payment is required within 5 days from receipt of invoice. PLEASE NOTE: payment must be received prior to the conference date. A receipt will be issued on payment. Due to limited conference space, we advise early registration to avoid disappointment. A 50% cancellation fee will be charged under the terms outlined below. We reserve the right to refuse admission if payment is not received on time. Unless otherwise stated on the booking form, payment must be made in pounds sterling.
3. Cancellation/Substitution: Provided the total fee has been paid, substitutions at no extra charge up to 14 days before the event are allowed. Substitutions between 14 days and the date of the event will be allowed subject to an administration fee of equal to 10% of the total fee that is to be transferred. Otherwise, all bookings carry a 50% cancellation liability immediately after a signed sales contract has been received by Mondial Research Group (as defined above). Cancellations must be received in writing by mail or fax (6) weeks before the conference is to be held in order to obtain a full credit for any future Mondial Research Group conference. Thereafter, the full conference fee is payable and is non-refundable. The service charge is completely non-refundable and non-credited. Payment terms are five days and payment must be made prior to the start of the conference. Non-payment or non-attendance does not constitute cancellation. By signing this contract, the client agrees that in case of dispute or cancellation of this contract Mondial Research Group will not be able to mitigate its losses for any less than 50% of the total contract value. If, for any reason, Mondial Research Group decides to cancel or postpone this conference, Mondial Research Group is not responsible for covering airfare, hotel, or other travel costs incurred by clients. The conference fee will not be refunded, but can be credited to a future conference. Event programme content is subject to change without notice.
4. Copyright: All intellectual property rights in all materials produced or distributed by Mondial Research Group in connection with this event are expressly reserved and any unauthorized duplication, publication or distribution is prohibited.
5. Client information is kept on Mondial Research Group companies database and used by Mondial Research Group companies to assist in providing selected products and services which maybe of interest to the Client and which will be communicated by letter, phone, fax, (inc. automatic dialing) email or other electronic means. If you do not want Mondial Research Group to do this please tick this box [ ]. For training and security purposes telephone calls maybe recorded.
6. Important note: While every reasonable effort will be made to adhere to the advertised package, Mondial Research Group reserves the right to change event dates, sites or location or omit event features, or merge the event with another event, as it deems necessary without penalty and in such situations no refunds, part refunds or alternative offers shall be made. In the event that Mondial Research Group permanently cancels the event for any reason whatsoever, (including, but not limited to any force or major occurrence) and provided that the event is not postponed to a later date nor is merged with another event, the Client shall receive a credit for the amount that the Client has paid to such permanently cancelled event, valid for up to one year to be used at another Mondial Research Group event. No refunds, part refunds or alternative offers shall be made.
7. Governing law: This Agreement shall be governed and construed in accordance with the law of England and the parties submit to the exclusive jurisdiction of the English Courts in London. Mondial Research Group only is entitled to waive this right and submit to the jurisdiction of the courts in which the Client’s office is located.